Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

Phil Powell, Indiana University professor of business economics, led off remarks on Wednesday with three statistics that he ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a ...

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk’s value more than quintupled between 2017 and 2024, but the company’s shares have fallen sharply since late last year, weighed down by Big Pharma rivals catching up and the ...

Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ETCompany ParticipantsJacob Rode - Head of Investor RelationsLars Jorgensen - ...

While Novo Nordisk is getting thrashed, Eli Lilly shares shot up by 14 percent in light of the latest news. As STAT points out , Novo Nordisk doesn't have any comparable small-molecule drug to Eli ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

Novo Nordisk is not the only company that has realized the potential of the GLP-1 market, ... Agnani (Italy), Brussels (Belgium) and Bloomington (United States). Through this acquisition, ...